GI Endoscopy · 6 min read
Esophageal Cancer in the West: Adenocarcinoma Rose, Squamous Fell, EAC Has Plateaued
This URL is epidemiology. Prague, Seattle protocol, and endoscopic therapy live on the Barrett page. Do not compete with it.
Worldwide, esophageal squamous cell carcinoma is still the common tumor. In the United States the histology flipped: adenocarcinoma rose through the 1990s and overtook squamous cancer in White men. Liu 2022 (PMID 36551535) using SEER 1992-2019: ESCC fell about 2.9% per year. EAC rose 5.2% per year from 1992 to 2000, then flattened (0.22% per year) through 2019. Obesity and reflux explain the rise. Smoking and alcohol explain the squamous fall. Surveillance technique is not this page.
Experienced teaching points
Clinical Pearls
- ESCC: mid and upper esophagus, smoking, alcohol, hot beverages, esophageal cancer belt.
- EAC: distal esophagus and GEJ, GERD, Barrett, central obesity. White men in the US.
- The US EAC surge slowed after 2000. Do not quote 1970s slopes as if they are still running.
- How to look at Barrett: Barrett surveillance page.
Clinical Bottom Line
| Histology | Where and why |
|---|---|
| Squamous cell carcinoma | Still the global majority. Upper and middle third. Smoking, alcohol, thermal injury. Falling in the US (Liu 2022 AAPC about -2.85%). |
| Adenocarcinoma | Western majority, distal third and GEJ. GERD, Barrett, obesity. Rose fast 1992-2000 (APC 5.17%), then plateaued (APC 0.22% to 2019). |
| What this page is not | Not Prague C&M, not Seattle protocol, not ablation. Those are the Barrett page. |
Did adenocarcinoma really overtake squamous?
Yes in the US, especially in White men, and over decades, not overnight. Liu and colleagues (PMID 36551535) used SEER 12, 1992-2019. Overall esophageal cancer incidence drifted down because squamous fell every year. Adenocarcinoma's steep climb of the 1990s did not continue as a straight line. After 2000 the joinpoint is essentially flat. Birth cohorts after 1950 no longer show the old EAC acceleration. That is the number to quote instead of "skyrocketing."
The biology story is still Barrett and reflux plus obesity. It does not make every heartburn patient a cancer. It does make a long-segment Barrett exam worth doing well. Technique: Barrett page.
What about the rest of the world?
Squamous cell carcinoma still dominates globally and along the esophageal cancer belt from northern Iran through Central Asia into northern China. Do not export US histology ratios onto a traveler from that belt. Their tumor is squamous until proven otherwise, and their risk factors are not a BMI chart.
Selected references
- Liu KS, Raza SA, El-Serag HB, Thrift AP. Trends in esophageal adenocarcinoma and esophageal squamous cell carcinoma incidence in the United States from 1992 to 2019. Cancers (Basel). 2022;14:6049.
- Barrett surveillance, Prague, Seattle protocol, EET: the Barrett page.
Last reviewed September 20, 2026. Written for clinicians who need the incidence story in one paragraph before they send someone to Barrett surveillance.
For your teaching file
Save this article as a PDF
Drop your email and we'll open a print-ready version you can save as a PDF — and you'll start getting our weekly GI endoscopy newsletter.